Phase II Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate the efficacy, safety and pharmacokinetics profile of KPS-0373 in patients with SCD

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Kissei Pharmaceutical Co., Ltd.
• Treatments: Thyrotropin-Releasing Hormone

Criteria

Inclusion Criteria:

• SCD with mild to moderate ataxia

Exclusion Criteria:

• Patients with secondary ataxia

• Patients with clinically significant hepatic, renal, or cardiovascular dysfunction